Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today provided an ...
Monogram May Market the Monogram mBôs™ TKA System, Subject to the Requirements of the Federal Food, Drug, and Cosmetic Act (the Act). The Company is Preparing for Commercialization and ...
Application was Submitted on July 19, 2024, Passed the FDA Administrative Review, and is Now Under Substantive Review FDA Decision is Expected Within 90 Days of Initial Submission; However, the ...
Hosted on MSN
MGRM: Monogram Receives Clearance from the FDA on its 510(k) Submission for its mBôs TKA System.
On March 17, 2025, Monogram (NASDAQ:MGRM) announced that the FDA has granted 510(k) clearance for its Monogram mBôs TKA System. This determination means that the company can move forward with upgrades ...
Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today provided an ...
AUSTIN, TX / ACCESS Newswire / March 17, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial ...
Management Anticipates That it has Sufficiently Addressed the FDA's Concerns to Mitigate the Need for a Clinical Data Request AUSTIN, TX / ACCESSWIRE / December 18, 2024 / Monogram Technologies Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results